A Phase 3 interventional study of Pregabalin and placebo in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 37 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.
Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 16th largest by enrollment, is one of 4 that started in 2011, is one of 13 in phase 3, and was the 19th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 14 · Phase 4 7
First in 2004; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 199 across the 30 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Fibromyalgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 13 (68%) have results posted.
Among the 19 studies in Fibromyalgia by Viatris Inc., this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2011, is one of 13 in phase 3, and was the 18th registered.
Viatris Inc.’s Fibromyalgia studies by the year they started, since 2004.
4 of the studies testing pregabalin in Fibromyalgia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07230197Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing pregabalin in Fibromyalgia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 19 in Fibromyalgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The intent of this study is to identify and treat fibromyalgia subjects with comorbid depression who are receiving an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) primarily for their depression and to determine whether pregabalin demonstrates improvement relative to placebo in improving pain associated with fibromyalgia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
Drug: Pregabalin
Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
Drug: placebo
Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
placebo capsules twice a day for 14 weeks
Mean NRS Pain Score at End of Period.
The daily pain diary consists of an 11-point numeric scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The endpoint mean pain scores for Period 1 and Period 2 are defined as the mean of the last 7 non-missing daily diary pain ratings while taking study medication in the double-blind phase during Period 1 and Period 2, respectively.
Time frame: End of each period, at Weeks 6 and 14
Fibromyalgia Impact Questionnaire (FIQ) Score at Baseline.
This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).
Time frame: Baseline
FIQ Score at End of Period.
This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).
Time frame: End of each period, at Weeks 6 and 14
Patient Global Impression of Change (PGIC) at the End of Period 1.
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).
Time frame: End of Period 1 at Week 6
Percentage of Participants With >=30% and >=50% Pain Reduction Based on Daily Pain Diary.
Participant with at least a 30% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 30% responder, for the respective period. Similarly, a subject with at least a 50% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 50% responder, for the respective period.
Time frame: Visits 2, 6, and 12
Subjective Sleep Questionnaire - Mean Sleep Quality at End of Period.
Subjective Sleep Questionnaire included 5 items: participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective rating of quality of sleep during the past night was done by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses was therefore 0-10.
Time frame: End of each period, at Weeks 6 and 14
Subjective Sleep Questionnaire - Mean Subjective Wake After Sleep Onset at End of Period.
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective wake after sleep onset was the subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening.
Time frame: End of each period, at Weeks 6 and 14
Subjective Sleep Questionnaire - Mean Latency to Sleep Onset at End of Period.
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective latency to sleep onset was the subjective estimate of the amount of time to fall asleep after lights out.
Time frame: End of each period, at Weeks 6 and 14
Subjective Sleep Questionnaire - Mean Subjective Total Sleep Time at End of Period.
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.
Time frame: End of each period, at Weeks 6 and 14
Subjective Sleep Questionnaire - Parameter Estimates for Subjective Number of Awakenings Per Night After Sleep Onset at End of Period.
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective number of awakenings after sleep onset was the subjective estimate of the total number of times the participant awakened during the night until final awakening.
Time frame: End of each period, at Weeks 6 and 14
Hospital Anxiety and Depression Scale (HADS) at Baseline.
HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline
HADS at End of Period.
HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: End of each period, at Weeks 6 and 14
Mean EuroQoL 5-Dimensions (EQ-5D) Score at Baseline.
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).
Time frame: Baseline
EQ-5D Score at End of Period.
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).
Time frame: End of each period, at Weeks 6 and 14
PGIC at the End of Period 2.
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Because of the crossover design and PGIC recall period (since starting study medication), the Period 1 PGIC data were felt to provide the clearest comparison across treatments, whereas Period 2 PGIC data were felt to have a more complex interpretation. Thus PGIC at End of Period 2 was separately analyzed from PGIC at End of Period 1.
Time frame: End of Period 2 at Week 14
Mean Patient Static Global Assessment (PSGA) Score at Baseline.
PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point NRS ranging from 0 (very poor) to 10 (very good).
Time frame: Baseline
Mean PSGA Score at End of Period.
PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point numeric rating scale (NRS) ranging from 0 (very poor) to 10 (very good).
Time frame: End of each period, at Weeks 6 and 14
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline.
C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) ("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").
Time frame: Baseline
Number of Participants With Categorical Scores on the C-SSRS at Post-Baseline.
C-SSRS assessed whether participant experienced following:completed suicide (1), suicide attempt (2) (response of Yes on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) (Yes on "preparatory acts or behavior"), suicidal ideation (4) (Yes on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) (Yes on "Has subject engaged in non-suicidal self-injurious behavior"). Below table indicated one participant (10141023) treated with Pregabalin reported preparatory act. However upon study unblinding it was clarified that preparatory act occurred while the participant was taking placebo. Since preparatory act was reported at first visit of Period 2, by convention statistical summaries classified this under Pregabalin treatment.
Time frame: From Visit 3 to Visit 14
Work Productivity and Activity Index-Specific Health Problem (WPAI-SHP) Questionnaire at Baseline.
WPAI-SHP assessed work productivity and impairment. It was a participant-rated, six-item questionnaire regarding current employment, hours missed and actually worked, and degree to which a specified health problem affected work productivity and regular activities over the past 7 days. Subscale scores included percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Each subscale score was expressed as an impairment percentage (0-100) where higher numbers indicated greater impairment and less productivity.
Time frame: Baseline
Health Utilization Assessment (Total Office Visits, Number of Hospitalizations and Number of Emergency Room Visits) at Baseline.
The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services.
Time frame: Baseline
Health Utilization Assessment (Time for Help no Payment) at Baseline.
The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services. 'Time for help no payment' refers to time other people spent without receiving payment to help with activities the patient cannot perform due to fibromyalgia.
Time frame: Baseline
In this double blind, crossover study, a total of 197 participants were randomized to either pregabalin/placebo or placebo/pregabalin treatment sequence. Of these, 193 took at least one dose of study medication. Four randomized participants never took study medication. Randomized participants were recruited from 4 countries at 38 study centers.
| Milestone | Pregabalin/Placebo | Placebo/Pregabalin |
|---|---|---|
| Started | 96 | 97 |
| Completed | 70 | 79 |
| Not completed | 26 | 18 |
The daily pain diary consists of an 11-point numeric scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The endpoint mean pain scores for Period 1 and Period 2 are defined as the mean of the last 7 non-missing daily diary pain ratings while taking study medication in the double-blind phase during Period 1 and Period 2, respectively.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Mean NRS Pain Score at End of Period. | 4.84 ± 0.15 | 5.45 ± 0.16 |
This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).
| Units on a scale | Pregabalin/Placebo | Placebo/Pregabalin |
|---|---|---|
| Total (N=96, 96) | 63.83 ± 11.58 | 62.75 ± 12.51 |
| Physical Impairment (N=96, 97) | 4.58 ± 2.10 | 4.44 ± 2.14 |
| Feel Good (N=96, 97) | 7.78 ± 2.47 | 7.43 ± 2.32 |
| Work Missed (N=96, 97) | 3.38 ± 2.88 | 3.49 ± 3.21 |
| Do Work (N=96, 97) | 6.61 ± 2.03 | 6.38 ± 2.21 |
| Pain (N=96, 96) | 6.98 ± 1.25 | 7.09 ± 1.32 |
| Fatigue (N=96, 97) | 8.17 ± 1.37 | 8.08 ± 1.58 |
| Rested (N=96, 97) | 7.90 ± 1.51 | 7.82 ± 1.96 |
| Stiffness (N=96, 97) | 7.56 ± 1.76 | 7.64 ± 1.58 |
| Anxiety (N=96, 97) | 5.65 ± 2.73 | 5.60 ± 2.59 |
| Depression (N=96, 97) | 5.23 ± 2.64 | 4.84 ± 2.55 |
This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Total (N=176, 172) | 43.78 ± 1.42 | 50.38 ± 1.43 |
| Physical impairment (N=176, 173) | 3.35 ± 0.17 | 3.77 ± 0.17 |
| Feel good (N=176, 173) | 4.69 ± 0.23 | 5.53 ± 0.23 |
| Work missed (N=176 , 173) | 2.02 ± 0.21 | 2.62 ± 0.21 |
| Do work (N=176, 172) | 4.56 ± 0.20 | 5.31 ± 0.20 |
| Pain (N=176, 173) | 4.91 ± 0.17 | 5.54 ± 0.17 |
| Fatigue (N=176, 173) | 6.32 ± 0.19 | 6.76 ± 0.19 |
| Rested (N=176, 173) | 5.64 ± 0.19 | 6.41 ± 0.19 |
| Stiffness (N=176, 173) | 5.24 ± 0.19 | 5.95 ± 0.19 |
| Anxiety (N=176, 173) | 3.80 ± 0.20 | 4.35 ± 0.21 |
| Depression (N=176, 173) | 3.20 ± 0.20 | 4.13 ± 0.20 |
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).
| Percentage of participants | Pregabalin | Placebo |
|---|---|---|
| Very much improved | 10.8 | 4.3 |
| Much improved | 35.5 | 25.8 |
| Minimally improved | 28.0 | 40.9 |
| No change | 17.2 | 21.5 |
| Minimally worse | 4.3 | 6.5 |
| Much worse | 3.2 | 1.1 |
| Very much worse | 1.1 | 0 |
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Because of the crossover design and PGIC recall period (since starting study medication), the Period 1 PGIC data were felt to provide the clearest comparison across treatments, whereas Period 2 PGIC data were felt to have a more complex interpretation. Thus PGIC at End of Period 2 was separately analyzed from PGIC at End of Period 1.
| Percentage of Participants | Pregabalin | Placebo |
|---|---|---|
| Very much improved | 18.3 | 8.6 |
| Much improved | 34.1 | 25.9 |
| Minimally improved | 28.0 | 38.3 |
| No change | 11.0 | 14.8 |
| Minimally worse | 6.1 | 8.6 |
| Much worse | 1.2 | 2.5 |
| Very much worse | 1.2 | 1.2 |
Participant with at least a 30% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 30% responder, for the respective period. Similarly, a subject with at least a 50% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 50% responder, for the respective period.
| Percentage of participants | Pregabalin | Placebo |
|---|---|---|
| 30% Responders | 45.3 | 27.7 |
| 50% Responders | 26.0 | 15.8 |
Subjective Sleep Questionnaire included 5 items: participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective rating of quality of sleep during the past night was done by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses was therefore 0-10.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Subjective Sleep Questionnaire - Mean Sleep Quality at End of Period. | 6.15 ± 0.14 | 5.57 ± 0.14 |
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective wake after sleep onset was the subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening.
| Minutes | Pregabalin | Placebo |
|---|---|---|
| Subjective Sleep Questionnaire - Mean Subjective Wake After Sleep Onset at End of Period. | 33.38 ± 2.73 | 41.18 ± 2.76 |
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective latency to sleep onset was the subjective estimate of the amount of time to fall asleep after lights out.
| Minutes | Pregabalin | Placebo |
|---|---|---|
| Subjective Sleep Questionnaire - Mean Latency to Sleep Onset at End of Period. | 33.54 ± 2.68 | 39.33 ± 2.71 |
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.
| Minutes | Pregabalin | Placebo |
|---|---|---|
| Subjective Sleep Questionnaire - Mean Subjective Total Sleep Time at End of Period. | 422.98 ± 5.42 | 414.63 ± 5.48 |
Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective number of awakenings after sleep onset was the subjective estimate of the total number of times the participant awakened during the night until final awakening.
| Number of times awakened | Pregabalin | Placebo |
|---|---|---|
| Subjective Sleep Questionnaire - Parameter Estimates for Subjective Number of Awakenings Per Night After Sleep Onset at End of Period. | 0.48 ± 0.07 | 0.61 ± 0.07 |
HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| Units on a scale | Pregabalin/Placebo | Placebo/Pregabalin |
|---|---|---|
| HADS-A (anxiety) | 8.67 ± 3.95 | 7.97 ± 3.77 |
| HADS-D (depression) | 8.34 ± 3.59 | 7.73 ± 3.64 |
HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| HADS-A (anxiety) | 6.01 ± 0.28 | 6.96 ± 0.28 |
| HADS-D (depression) | 6.17 ± 0.31 | 7.05 ± 0.31 |
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).
| Units on a scale | Pregabalin/Placebo | Placebo/Pregabalin |
|---|---|---|
| Mean EuroQoL 5-Dimensions (EQ-5D) Score at Baseline. | 0.40 ± 0.31 | 0.37 ± 0.33 |
EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| EQ-5D Score at End of Period. | 0.58 ± 0.02 | 0.56 ± 0.02 |
PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point NRS ranging from 0 (very poor) to 10 (very good).
| Units on a scale | Pregabalin/Placebo | Placebo/Pregabalin |
|---|---|---|
| Mean Patient Static Global Assessment (PSGA) Score at Baseline. | 4.35 ± 2.04 | 4.46 ± 1.92 |
PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point numeric rating scale (NRS) ranging from 0 (very poor) to 10 (very good).
| Units on a scale | Pregabalin | Placebo |
|---|---|---|
| Mean PSGA Score at End of Period. | 5.83 ± 0.17 | 5.27 ± 0.17 |
C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) ("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").
| Participants | Pregabalin/Placebo | Placebo/Pregabalin |
|---|---|---|
| Wish to be Dead | 3 | 1 |
| Non-Specific Thoughts | 0 | 1 |
| Without Intent to Act | 0 | 0 |
| Some Intent to Act | 0 | 0 |
| Specific Plan and Intent | 0 | 0 |
| Actual Attempt | 0 | 0 |
| Non-Suicidal Self-Injurious Behavior | 0 | 0 |
| Interrupted Attempt | 0 | 0 |
| Aborted Attempt | 0 | 0 |
| Preparatory Acts or Behavior | 0 | 0 |
| Suicidal Behavior Present | 0 | 0 |
| Completed Suicide | 0 | 0 |
C-SSRS assessed whether participant experienced following:completed suicide (1), suicide attempt (2) (response of Yes on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) (Yes on "preparatory acts or behavior"), suicidal ideation (4) (Yes on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) (Yes on "Has subject engaged in non-suicidal self-injurious behavior"). Below table indicated one participant (10141023) treated with Pregabalin reported preparatory act. However upon study unblinding it was clarified that preparatory act occurred while the participant was taking placebo. Since preparatory act was reported at first visit of Period 2, by convention statistical summaries classified this under Pregabalin treatment.
| Participants | Pregabalin | Placebo |
|---|---|---|
| Wish to be Dead | 10 | 8 |
| Non-Specific Thoughts | 3 | 1 |
| Without Intent to Act | 2 | 0 |
| Some Intent to Act | 0 | 0 |
| Specific Plan and Intent | 0 | 0 |
| Actual Attempt | 0 | 0 |
| Non-Suicidal Self-Injurious Behavior | 0 | 0 |
| Interrupted Attempt | 0 | 0 |
| Aborted Attempt | 0 | 0 |
| Preparatory Acts or Behavior | 1 | 0 |
| Suicidal Behavior Present | 1 | 0 |
| Completed Suicide | 0 | 0 |
WPAI-SHP assessed work productivity and impairment. It was a participant-rated, six-item questionnaire regarding current employment, hours missed and actually worked, and degree to which a specified health problem affected work productivity and regular activities over the past 7 days. Subscale scores included percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Each subscale score was expressed as an impairment percentage (0-100) where higher numbers indicated greater impairment and less productivity.
| Units on a scale | All Participants |
|---|---|
| Percent Absenteeism (N= 86) | 15.22 ± 25.36 |
| Percent Presenteeism (N= 83) | 53.98 ± 21.52 |
| Percent Overall Work Impairment (N= 82) | 57.96 ± 23.42 |
| Percent Activity Impairment (N=193) | 64.97 ± 18.77 |
The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services.
| Visits | All Participants |
|---|---|
| Total office visits (N= 193) | 5.01 ± 6.6 |
| Number of hospitalizations (N= 0) | NA ± NA |
| Number of emergency room visits (N= 12) | 1.83 ± 1.0 |
The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services. 'Time for help no payment' refers to time other people spent without receiving payment to help with activities the patient cannot perform due to fibromyalgia.
| Hours | All Participants |
|---|---|
| Health Utilization Assessment (Time for Help no Payment) at Baseline. | 50.37 ± 98.1 |
Collected over Up to Week 16. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 3/181 (1.7%) | 139/181 (76.8%) |
| Placebo | — | 1/177 (0.6%) | 106/177 (59.9%) |
| Event | Pregabalin | Placebo |
|---|---|---|
| Brain neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/181 | 1/177 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/181 | 0/177 |
| AnxietyPsychiatric disorders | 1/181 | 0/177 |
| DetoxificationSurgical and medical procedures | 1/181 | 0/177 |
| Event | Pregabalin | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 51/181 | 12/177 |
| SomnolenceNervous system disorders | 36/181 | 8/177 |
| ConstipationGastrointestinal disorders | 19/181 | 4/177 |
| HeadacheNervous system disorders | 14/181 | 17/177 |
| NauseaGastrointestinal disorders | 17/181 | 12/177 |
| DiarrhoeaGastrointestinal disorders | 16/181 | 7/177 |
| Weight increasedInvestigations | 16/181 | 3/177 |
| InsomniaPsychiatric disorders | 13/181 | 1/177 |
| Dry mouthGastrointestinal disorders | 12/181 | 1/177 |
| FatigueGeneral disorders | 12/181 | 8/177 |
| Age, Customized(Participants) | Pregabalin/Placebo | Placebo/Pregabalin | Total |
|---|---|---|---|
| < 18 Years | 0 | 0 | 0 |
| 18-44 Years | 22 | 29 | 51 |
| 45-64 Years | 69 | 60 | 129 |
| >= 65 Years | 5 | 8 | 13 |
| Sex: Female, Male(Participants) | Pregabalin/Placebo | Placebo/Pregabalin | Total |
|---|---|---|---|
| Female | 87 | 93 | 180 |
| Male | 9 | 4 | 13 |
The record gives a start of Oct 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →